Pioneering innovative API manufacturing solutions
Explore our group
Our Group in numbers
One group. Three stories.
Millions of patients served.
Novasep CDMO strengthens its innovative position in oncology
We invested €8 million in our Le Mans (Fr) site to expand our production capabilities for manufacturing ADCs. Behind every pharma project, there are high-quality services for our customers and cutting-edge drugs for millions of patients worldwide.
Combining strengths to provide existing and innovative treatments for patients
“Axplora possess a unique blend of technical expertise (chromatography and small molecule manufacturing), interpersonal skills, and a dedication to excellence that makes them an exceptional CMO. We are fortunate to have such a strong partnership with the Axplora team!”
“The Axplora team was very open, flexible and efficient in working through project changes.”
Martin Meeson - CEO
DCAT Value Chain Insights - Industry Roundtable: Small-Molecule APIs - January 2025
"The continued rising demand for complex APIs, particularly in areas such as GLP-1 receptor agonists for metabolic disorders and antibody-drug conjugates (ADCs) for oncology, increases the need for advanced manufacturing expertise and specialized facilities."
Axplora in the news
Axplora expands commercial payload production capabilities at Le Mans to strengthen its leading position in ADC Manufacturing
Axplora announces €50 Million Investment in GLP-1 Manufacturing at Mourenx (France) Site
Martin Meeson appointed as CEO of Axplora
